Published 3 months ago • loading... • Updated 3 months ago
Ozempic may be reshaping the brain, scientists say
Researchers found the pills also reduced dopamine signaling in a brain reward circuit, pointing to possible uses beyond weight loss.
A new NIH-funded study published in Nature on May 6 reveals that oral GLP-1 weight-loss drugs target a deep-brain reward circuit, dampening 'hedonic feeding'—eating motivated by pleasure rather than hunger.
Researchers found these oral compounds activate the central amygdala, a brain region tied to desire and reward that scientists previously did not believe GLP-1 drugs could directly access, reducing dopamine release during pleasure-driven eating.
Investigating small-molecule drugs including orforglipron and danuglipron, the team mapped activated brain regions in mice; scientists are now planning to determine if these newer medications can also reduce cravings unrelated to food.
"Now it seems oral small-molecule GLP-1s also dial back eating for pleasure by engaging a brain reward circuit," said co-corresponding author Ali Guler, suggesting potential for treating addiction.
Future studies will examine the drugs' potential effects on substance use disorder; as medication accessibility rises, experts emphasize understanding the neural mechanisms underlying these complex behavioral effects.